Here are relevant reports on : gene-synthesis-market
-
Gene Expression Analysis Market by Product (Reagents, Enzymes, Kits, DNA Chips, PCR, NGS, DNA Microarray), Service (RNA Sequencing, Bioinformatics), Application (Drug discovery & Development, Clinical Diagnostics), End User & Region - Global Forecast to 2029
The global gene expression analysis market, valued at US$3.9 billion in 2023, stood at US$4.2 billion in 2024 and is projected to advance at a resilient CAGR of 8.1% from 2024 to 2029, culminating in a forecasted valuation of US$6.2 billion by the end of the period. Growth in this market is primarily driven by the increasing investments by pharmaceutical & biotechnology companies for genome based studies.
- Published: March 2024
- Price: $ 4950
- TOC Available:
-
Cryo-electron Microscopy Market by Product & Service (Instruments, Software, Services), Technology (Electron Crystallography, Cryo-ET), Voltage (300 kV), Application (Cancer, Omics, Gene Therapy, Nanotechnology, Vaccine) & Region - Global Forecasts to 2028
The global cryo-electron microscopy market in terms of revenue was estimated to be worth $1.1 billion in 2022 and is poised to reach $2.1 billion by 2028, growing at a CAGR of 11.6% from 2022 to 2028. As of 2021, prominent players in the global market are Thermo Fisher Scientific (US), Danaher (US), JEOL Ltd. (Japan), Intertek Group Plc (UK), and Charles River Laboratories (US).
- Published: March 2023
- Price: $ 4950
- TOC Available:
-
Leukapheresis Market by Type (Filter, Membrane Separator, Centrifugal Device), Leukopak (Mobilized, Isolated PBMC), Application (Research [Cell & Gene Therapy, Transplantation], Therapeutic), Indication, End User, Region - Global Forecast to 2031
The global Leukapheresis market, valued at USD 83.3 billion in 2025, stood at USD 90.6 billion in 2026 and is projected to advance at a resilient CAGR of 8.9% from 2026 to 2031, culminating in a forecasted valuation of USD 138.7 billion by the end of the period. This growth is driven by the increasing number of therapeutic and manufacturing applications for leukapheresis in hematologic disorders, as well as the rising demand for high-quality starting materials used in cell and gene therapy, including CAR-T, TCR, and NK-cell programs.
- Published: April 2026
- Price: $ 4950
- TOC Available:
-
Viral Inactivation Market by Product (Kits, Reagents, Systems, Services), Application (Stem Cell, Blood, Tissue, Cell & Gene Therapy), Method (Solvent Detergent, Pasteurization) & End User (Pharmaceutical and Biotechnology, CROs) - Global Forecast to 2021
The global viral inactivation market is segmented on the basis of method, product, application, end user, and geography. By method, the market is divided into solvent detergent method, pasteurization, and other methods. The global viral inactivation market was valued at USD 320.5 Million in 2016. This market is expected to grow at a CAGR of 12.3% to reach USD 573.0 Million in 2021.
- Published: June 2016
- Price: $ 4950
- TOC Available:
-
Gene Panel Market by Product & Service, Technique (Amplicon, Hybridization), Design (Predesign, Custom), Application (Cancer, Congenital Disease, Pharmacogenetics) & End User (Hospital, Research Center, Pharmaceutical Companies) - Global Forecasts to 2023
The global gene panel market is expected to reach USD 2.95 Billion by 2023, at a CAGR of 19.2%. The growth of this market is mainly driven by the increasing prevalence of chronic diseases, growing company initiatives, and rising adoption of gene panel owing to the benefits they offer. The gene panel market is fragmented, with the presence of several large as well as emerging players. Prominent players in the gene panels market include Illumina, Inc. (US), BGI (China), Agilent Technologies (US), Eurofins Scientific (US), QIAGEN (Germany), GENEWIZ, Inc. (US), Novogene Corporation (China), Personalis (US), Thermo Fisher Scientific (US), F. Hoffmann-La Roche AG (Switzerland), Integrated DNA Technologies (IDT) (US), GATC Biotech AG (GATC Biotech) (Germany), and ArcherDx (US). Players in this market are adopting various organic and inorganic strategies, such as product launches & upgradations, agreements, partnerships, joint ventures, collaborations, and acquisition to widen their product portfolios and expand their presence in the market.
- Published: May 2018
- Price: $ 4950
- TOC Available:
-
Biologics Safety Testing Market by Product & Service (Consumables, Instrument, Services), Test Type (Mycoplasma, Sterility, Endotoxin, Bioburden, Virus Safety), Application (Vaccines, mAbs, Cell & Gene Therapy, Blood Products) - Global Forecast to 2029
The global biologics safety testing market, valued at US$3.9 billion in 2023, stood at US$4.2 billion in 2024 and is projected to advance at a resilient CAGR of 11.1% from 2024 to 2029, culminating in a forecasted valuation of US$7.2 billion by the end of the period. Growth of the market can be attributed to factors such as the rising need for novel biotherapeutics and increasing focus on advancement of biopharmaceutical industry.
- Published: May 2024
- Price: $ 4950
- TOC Available:
-
Regenerative Medicine Market by Product (Stem Cell [Autologous, Allogenic], Immunotherapy, Gene Therapy, Tissue Engineering), Application (Musculoskeletal, Cancer, Dermatology, Wound care, Cardiovascular Diseases, Eye Disorders) & Region - Global Forecast to 2028
The global regenerative medicine market, valued at US$13.5 billion in 2022, stood at US$16.0 billion in 2023 and is projected to advance at a resilient CAGR of 25.1% from 2023 to 2028, culminating in a forecasted valuation of US$49.0 billion by the end of the period. The growth of this market is characterized by the increasing collaborations and partnerships by major market players, and the emerging applications in new therapeutic areas. Rising focus on personalized medicine and increasing regulatory approvals in regenerative medicine are also predicted to drive the market.
- Published: January 2024
- Price: $ 4950
- TOC Available:
-
Recombinant Proteins Market by Product (Growth Factors, Chemokines, Structural Proteins, Membrane Proteins), Application (Drug Discovery & Development (Biologics, Vaccines, Cell & Gene Therapy), Research, Biopharma Production) & Region - Global Forecast to 2028
The global recombinant proteins market, valued at US$2.1 billion in 2022, stood at US$2.2 billion in 2023 and is projected to advance at a resilient CAGR of 7.2% from 2023 to 2028, culminating in a forecasted valuation of US$3.2 billion by the end of the period. Growth in the market can be attributed to factors such as rising incidence of chronic diseases, growing demand for biologics and biosimilars due to expiration of patents, rising demand for customized medicine and increasing government initiatives for R&D in life sciences research.
- Published: January 2024
- Price: $ 4950
- TOC Available:
-
Continuous Bioprocessing Market by Product (Chromatography, Filtration, Bioreactor, Media), Process (Upstream, Downstream), Scale of Operation (Commercial, Clinical), Application (mAbs, Vaccines, Cell & Gene Therapy), & End User - Global Forecast to 2028
The global continuous bioprocessing market, valued at US$201 million in 2022, stood at US$218 million in 2023 and is projected to advance at a resilient CAGR of 22.4% from 2023 to 2028, culminating in a forecasted valuation of US$599 million by the end of the period. The growth of the market is largely driven by rising demand for biopharmaceuticals, advantages of continuous bioprocessing over batch/fed-batch mode, and emergence of integrated end-to-end continuous bioprocessing.
- Published: November 2023
- Price: $ 4950
- TOC Available:
-
Viral Vector & Plasmid DNA Manufacturing Market by Type (Viral Vector (Retroviruses, Adenoviruses, AAV, Lentiviruses), Plasmid DNA), Workflow (Upstream, Downstream), Application (Cell & Gene Therapy), Diseases (Cancer), End User - Global Forecast to 2028
The global viral vector manufacturing market, valued at US$4.8 billion in 2022, stood at US$5.5 billion in 2023 and is projected to advance at a resilient CAGR of 18.2% from 2023 to 2028, culminating in a forecasted valuation of US$12.8 billion by the end of the period. The growth of this market is majorly driven by g rising prevalence of target diseases and disorders, the availability of funding for gene therapy development, and effectiveness of viral vectors in gene therapy delivery.
- Published: June 2023
- Price: $ 4950
- TOC Available:
Records 11 to 20 of 50
